Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma - Trial NCT06297226
Access comprehensive clinical trial information for NCT06297226 through Pure Global AI's free database. This Phase 2 trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company and is currently Recruiting. The study focuses on Multiple Myeloma. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Timeline & Enrollment
Phase 2
Mar 21, 2024
Jun 04, 2030
Primary Outcome
Best overall response (BOR)
Summary
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in
 participants with relapsed or refractory multiple myeloma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06297226
Non-Device Trial